Kiromic BioPharma Inc. (KRBP)
OTC: KRBP
· Real-Time Price · USD
0.20
0.00 (0.05%)
At close: Mar 24, 2025, 3:59 PM
Kiromic BioPharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 557K | 557K | 1.13M | 560.1K | 695K | n/a | 949.1K | n/a | 399.1K | 182.8K | 136.4K | 131K | n/a | n/a |
Gross Profit | n/a | n/a | -557K | -557K | -1.13M | -560.1K | -695K | n/a | -949.1K | n/a | -399.1K | -182.8K | -136.4K | -131K | n/a | n/a |
Operating Income | -5.71M | -6.6M | -6.35M | -5.11M | -5.32M | -5.55M | -4.29M | -4.78M | -6.92M | -8.4M | -8.43M | -7.37M | -10.66M | -6.14M | -4.97M | -3.96M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | -365.6K | -79K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -6.49M | -7.43M | -6.83M | -6.15M | -4.69M | -4.19M | -6.76M | -5.3M | -7.07M | -11.86M | -8.44M | -7.37M | -10.64M | -6.12M | -4.97M | -3.85M |
Net Income | -6.49M | -7.43M | -6.91M | -6.15M | -4.69M | -4.19M | -6.76M | -5.3M | -7.05M | -11.95M | -8.44M | -7.37M | -10.64M | -6.12M | -4.97M | -3.85M |
Selling & General & Admin | 2.17M | 2.38M | 1.66M | 2.09M | 2.41M | 2.87M | 2.33M | 2.7M | 3.59M | 4.61M | 4.55M | 4.44M | 6.9M | 2.66M | 2.31M | 2.07M |
Research & Development | -4.53M | 4.23M | 4.13M | 3.02M | 2.91M | 2.68M | 1.97M | 2.08M | 3.33M | 3.78M | 3.88M | 2.93M | 3.34M | 3.49M | 2.66M | 1.89M |
Other Expenses | 8.07M | n/a | 485K | 36K | 1.26M | 1.79M | -1.77M | n/a | n/a | n/a | n/a | n/a | 35.4K | 18K | n/a | n/a |
Operating Expenses | 5.71M | 6.6M | 5.8M | 5.11M | 5.32M | 5.55M | 4.29M | 4.78M | 6.92M | 8.4M | 8.43M | 7.37M | 10.23M | 6.14M | 4.97M | 3.96M |
Interest Expense | 766K | 935K | 957K | 1.07M | 632.9K | 433.8K | 335.4K | 444K | 159.6K | 1.4K | 2.7K | 2.8K | 5.9K | 500.00 | 2.1K | 3.7K |
Selling & Marketing Expenses | n/a | n/a | -557K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.71M | 6.6M | 6.35M | 5.11M | 5.32M | 5.55M | 4.29M | 4.78M | 6.92M | 8.4M | 8.43M | 7.37M | 10.23M | 6.14M | 4.97M | 3.96M |
Income Tax Expense | n/a | n/a | 86K | -557K | 1.89M | 2.23M | 335.4K | n/a | -12.8K | 88.3K | 2.7K | 2.8K | -36.4K | 18.5K | n/a | 3.7K |
Shares Outstanding (Basic) | 28.52M | 30.97M | 45.18M | 39.14M | 32.93M | 35.7M | 31.63M | 872.82K | 18.23M | 15.84M | 15.73M | 15.54M | 15.53M | 15.37M | 7.35M | 7.33M |
Shares Outstanding (Diluted) | 28.52M | 30.97M | 45.18M | 39.14M | 32.93M | 35.7M | 31.63M | 872.82K | 18.23M | 15.84M | 15.73M | 15.54M | 15.53M | 15.37M | 7.35M | 7.33M |
EPS (Basic) | -0.31 | -0.31 | -4.59 | -4.71 | -4.27 | -3.52 | -6.42 | -6.17 | -11.61 | -22.63 | -16.09 | -14.23 | -20.55 | -11.96 | -20.32 | -15.77 |
EPS (Diluted) | -0.31 | -0.31 | -4.59 | -4.71 | -4.27 | -3.52 | -6.42 | -6.17 | -11.61 | -22.63 | -16.09 | -14.23 | -20.55 | -11.96 | -20.32 | -15.77 |
EBITDA | -5.16M | -5.95M | -5.31M | -4.52M | -2.93M | -3.2M | -5.73M | -4.3M | -5.96M | -11.32M | -8.03M | -7.18M | -10.49M | -5.99M | -4.87M | -3.76M |
EBIT | -5.72M | -6.5M | -5.87M | -5.08M | -4.06M | -3.76M | -6.43M | -4.86M | -6.91M | -11.86M | -8.43M | -7.37M | -10.63M | -6.12M | -4.97M | -3.85M |
Depreciation & Amortization | 568K | 552K | 557K | 557K | 1.13M | 560.1K | 695K | 556K | 949.1K | 536.6K | 399.1K | 182.8K | 136.4K | 131K | 106.8K | 95.6K |